Skip to Content
Merck
  • β2-Adrenergic receptor activation on donor cells ameliorates acute GvHD.

β2-Adrenergic receptor activation on donor cells ameliorates acute GvHD.

JCI insight (2020-05-22)
Hemn Mohammadpour, Joseph L Sarow, Cameron R MacDonald, George L Chen, Jingxin Qiu, Umesh C Sharma, Xuefang Cao, Megan M Herr, Theresa E Hahn, Bruce R Blazar, Elizabeth A Repasky, Philip L McCarthy
ABSTRACT

Acute graft versus host disease (aGvHD) remains a major impediment to successful allogeneic hematopoietic cell transplantation (allo-HCT). To solve this problem, a greater knowledge of factors that regulate the differentiation of donor T cells toward cytotoxic cells or Tregs is necessary. We report that the β2-adrenergic receptor (β2-AR) is critical for regulating this differentiation and that its manipulation can control aGvHD without impairing the graft-versus-tumor (GvT) effect. Donor T cell β2-AR expression and signaling is associated with decreased aGvHD when compared with recipients of β2-AR-/- donor T cells. We determined that β2-AR activation skewed CD4+ T cell differentiation in vitro and in vivo toward Tregs rather than the T helper 1 (Th1) phenotype. Treatment of allo-HCT recipients with a selective β2-agonist (bambuterol) ameliorated aGvHD severity. This was associated with increased Tregs, decreased cytotoxic T cells, and increased donor BM-derived myeloid-derived suppressor cells (MDSCs) in allogeneic and humanized xenogeneic aGvHD models. β2-AR signaling resulted in increased Treg generation through glycogen synthase kinase-3 activation. Bambuterol preserved the GvT effect by inducing NKG2D+ effector cells and central memory T cells. These data reveal how β-AR signaling can be targeted to ameliorate GvHD severity while preserving GvT effect.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Bambuterol hydrochloride, >98% (HPLC), powder